Read + Share
Singh S, Heien HC, Sangaralingham L, Shah ND, et al. Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-alpha
Antagonists in Patients with Inflammatory Bowel Diseases. Dig Dis Sci 2022;67:2510-2516.
PMID: 34085174
|
 |
|
Singh S, Heien HC, Sangaralingham L, Shah ND, et al. Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-alpha
Antagonists in Patients with Inflammatory Bowel Diseases. Dig Dis Sci 2022;67:2510-2516.
PMID: 34085174
|
|
|
|